Product Description
APH03867 tablets are a novel, orally administered, non-peptide small-molecule URAT1 (Urate Transporter 1) inhibitor independently developed by the company. By inhibiting URAT1 activity in the kidneys, the drug blocks uric acid reabsorption in renal tubules, enhances uric acid excretion, and effectively lowers serum uric acid levels, thereby improving symptoms of hyperuricemia and gout. (Sourced from: https://news.futunn.com/en/post/74766486/yipinhong-300723-sz-announced-that-its-wholly-owned-subsidiary-s?level=1&data_ticket=1787244321238429)
Mechanisms of Action: URAT1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Guangzhou Yipinhong Pharmaceutical
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Gout
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|